Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).
NCT ID: NCT05946330
Last Updated: 2023-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
10 participants
INTERVENTIONAL
2023-02-22
2024-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Researchers will compare intervention group (IG) and Control Group (CG) and to see the effects of nutritional intervention. The expected primary outcome will be weight loss of 5% to 10% of the initial weight and the secondary outcomes will be: reduction in abdominal circumference and body mass index, and improvement in the levels of liver transaminases. Data will be analyzed with descriptive and inferential statistics.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quality of Life in Non-alcoholic Fatty Liver Disease (QOLNAFLD)
NCT03613480
Probiotics in the Treatment of NAFLD
NCT02764047
Impact of NAFLD vs MAFLD Stigma on Quality of Life in Egyptian Patients
NCT06503068
Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH
NCT05357248
Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment
NCT04308980
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Considering:
* That NAFLD e has gained alarming proportions, affecting 25 to 30% of the world's population and its occurrence is associated with overweight, insulin resistance and metabolic syndrome;
* That the morbidity and mortality associated with NAFLD has increased significantly, along with the growth of overweight in the population, and that there is still no specific marker for the diagnosis, nor a pharmacological treatment for the disease
* That prevention and treatment are based on lifestyle changes, with the adoption of healthy eating habits, which must necessarily lead to weight loss, in order to improve the condition
* That Food and Nutrition Education (EAN) is a tool for adopting healthy eating habits;
* That the Process of Care in Nutrition (PCN) is a tool that covers the domains of action of nutritionists in their clinical practice
* That nutritional literacy, understood as the ability to process and understand nutritional information is a factor for the success of EAN;
* That EAN can be seen as a set of experiences designed to facilitate the voluntary adoption of behavioral changes related to nutrition, health and well-being; It is
* That the development of educational strategies that promote better health indicators since low LN is associated with an increase in diet-related chronic diseases.
This research is justified considering that the nutritionist's role can help reduce and improve the factors that aggravate NAFLD and improve quality of life.
RESEARCH OBJECTIVE:
MAIN GOAL
-Verify the effectiveness of the educational action of the nutritionist for NAFLD and its interference in the nutritional status of the population of users of the Hepatic Steatosis Ambulatory of the Complexo de Hospital de Clínicas of UFPR.
SPECIFIC OBJECTIVES
* To characterize the nutritional profile of users with NAFLD at the Hepatic Steatosis Outpatient Clinic of the Complexo de Hospital de Clínicas of UFPR.
* Identify the interference of educational activity in nutrition literacy
* Compare dietary, anthropometric, clinical and functional indicators after intervention;
SOCIAL RELEVANCE:
Non-alcoholic fatty liver disease (NAFLD) is currently considered an epidemic disease, with a prevalence of 10 to 24% in the general population and 57% to 74% among obese people. Its presentation and severity can vary significantly, from a simple steatosis (deposition of fatty acids without inflammation) to Non-Alcoholic Steatohepatitis (NASH) with the presence of inflammation, ballooning and liver fibrosis in its final stage. There is an association of the disease with central obesity, insulin resistance and dyslipidemia. With the increase in the incidence of overweight and Metabolic Syndrome in the general population, NAFLD has become a serious public health problem, being considered the hepatic manifestation of the Metabolic Syndrome.
In most obese individuals or with adequate body mass index (BMI), and in treatment of other comorbidities, NAFLD may be present, with or without laboratory alterations such as elevations in aminotransferase levels, and for diagnostic confirmation it is necessary to perform exams such as ultrasound, or MRI or liver biopsy.
Currently, NAFLD does not have drugs that can be used for targeted conventional treatment, as it can only be treated and alleviated by controlling metabolic disorders. Thus, the treatment of NAFLD aims to reduce insulin resistance and oxidative stress, in addition to controlling associated conditions such as obesity, diabetes mellitus, dislipidemia and also to reduce inflammation and liver fibrosis. As the clinical picture of NAFLD becomes clearer, there are also challenges to developing an effective treatment. Thus, it appears that currently there are no pharmaceutical therapies approved by the Food and Drug Administration (FDA) to treat nonalcoholic steatosis (Nonalcoholic steatohepatitis - NASH).
The improvement of the NAFLD condition necessarily involves a decrease in the mass of adipose tissue. However, it is emphatic that drastic caloric restrictions, despite leading to rapid weight loss, are not recommended due to the increased concentration of circulating fatty acids, mobilized from the adipose tissue, which can increase their influx into the liver, aggravating the condition.
Although sustained weight loss of 3% to 5% can already lead to clinically significant reductions in some cardiovascular risk factors, weight losses greater than this margin yield greater benefits. An initial goal of losing 5% to 10% of the initial weight in six months is feasible to reduce complications. For this to happen, one of the tools is diet therapy monitoring and Food and Nutrition Education (EAN).
EAN is a set of systematized strategies to encourage the culture and appreciation of food, conceived in recognition of the need to respect, but also to adjust beliefs, values, attitudes, practices and social relationships that are established around food, with a view to economic and social access to adequate food in quality and quantity, which meets the objectives of health, pleasure and social life.
Still, the strengthening of ties with the multidisciplinary team, with the inclusion of a nutritionist in the systematized diet therapy educational activity, can increase the quality of life of the population under study.
SCIENTIFIC BACKGROUND: In the world, malnutrition in all its forms, including malnutrition, obesity and other dietary risks, for the development of chronic non-communicable diseases (NCDs), corresponds to 19% of the causes of illnesses and premature deaths in everyone. Among the NCDs related to malnutrition, non-alcoholic fatty liver disease (NAFLD) stands out, a syndrome that occurs in non-alcoholic patients, but who present liver damage histologically indistinguishable from alcoholic steatohepatitis.
CASUISTRY Nutritional intervention, when followed correctly, is effective in treating NAFLD in patients who achieve a minimum weight loss of 5% of their baseline body weight after 6 months of dietary therapy. Important alterations in the parameters of insulin resistance and metabolic syndrome are observed in these patients. Even an average reduction of only 2% of the initial body weight (non-adherent group) led to a decrease in some anthropometric parameters, such as BMI and waist circumference, when compared with baseline values. However, patients who lost at least 5% of their initial weight (adherent group) showed more pronounced reductions in these parameters, in addition to improvements in waist-hip ratio, glucose, insulin, HDL-C and LDL-C, alterations not observed in patients non-adherent.
RESEARCH MATERIAL:
For data collection, a form with clinical, dietary and socioeconomic data prepared by the researchers will be used. For the analysis of food intake, a 24-hour recall will be used and the assessment of Nutritional Literacy will be measured using the Nutritional Literacy Scale - NLS - Brazilian version.
PROPOSED METHOD:
Randomized controlled clinical trial with division into two groups (GI and CG) matched 1 to 1. Essentially, it is a study in which participants already seen at the Hepatic Steatosis Outpatient Clinic will be invited to participate and will be randomly allocated (participants are randomized) to receive one or more interventions. Clinical trial results can be directly incorporated into everyday clinical practice. Allocation to the intervention will be performed by simple randomization technique in a 1:1 ratio.
The intervention group will receive individual nutrition education actions with nutrition consultation (in person at the beginning and at 180 days of the intervention and phone calls and text messages at 30, 60, 90, 120 and 150, 240 and 300 days of follow-up. The group The control will receive the usual care at the Outpatient Clinic. The collection of clinical, anthropometric, sociodemographic and food consumption data will be carried out during the nutrition consultations, as well as the application of the NLS-Br Nutritional Literacy questionnaire to verify literacy. During the nutrition consultation A 24-hour recall will be carried out to collect information on food consumption.
They will also be carried out as monthly telephone contacts or messages via instant messaging application, to solve the doubts of the participants and notify them of upcoming meetings, and subsequent comparison of the LN in the target population. All interventions will be recorded in specific instruments for this purpose
EXPECTED OUTCOME It is expected that patients assisted by the nutritionist will have an improvement in the prognosis of non-alcoholic fatty liver disease (NAFLD), reduction in body weight and centripetal adipose mass, modification of lifestyle and increase in nutritional literacy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients will be followed up for one year by nutritionist intervention, on individual goals
Patients allocated in the study will be randomized 1:1 and followed up for one (1) year, intervention group (IG) with nutritionist consultations, nutritional diagnosis and educational intervention with agreement on individual goals.
NUTRITIONAL EDUCATIONAL INTERVENTION IN FATTY LIVER DISEASE NON-ALCOHOLIC (NAFLD).
The intervention group will receive educational actions in individual nutrition with nutrition consultation (in person at the beginning and at 180 days of the intervention and phone calls and text messages at 30, 60, 90, 120 and 150, 240 and 300 days of follow-up
Control Group (CG) will maintain the usual outpatient care.
Patients in the Control Group (CG) will maintain the usual outpatient care.
NUTRITIONAL EDUCATIONAL INTERVENTION IN FATTY LIVER DISEASE NON-ALCOHOLIC (NAFLD).
The intervention group will receive educational actions in individual nutrition with nutrition consultation (in person at the beginning and at 180 days of the intervention and phone calls and text messages at 30, 60, 90, 120 and 150, 240 and 300 days of follow-up
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NUTRITIONAL EDUCATIONAL INTERVENTION IN FATTY LIVER DISEASE NON-ALCOHOLIC (NAFLD).
The intervention group will receive educational actions in individual nutrition with nutrition consultation (in person at the beginning and at 180 days of the intervention and phone calls and text messages at 30, 60, 90, 120 and 150, 240 and 300 days of follow-up
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidade Federal do Paraná
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Doutorado Enfermagem
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maria F Mantovani, Dr
Role: PRINCIPAL_INVESTIGATOR
Universidade Federal do Paraná
Maria E Schieferdecker, Dr
Role: STUDY_CHAIR
Universidade Federal do Paraná
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Clínicas da Universidade Federal do Paraná
Curitiba, Paraná, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
The Brazilian Registry of Clinical Trials (ReBEC) is a free access virtual platform for recording experimental and non-experimental studies carried out on human beings and conducted in Brazilian territory, by Brazilian and foreign researchers.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UFPRENFERMAGEM
Identifier Type: OTHER
Identifier Source: secondary_id
UFPRENFERMAGEM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.